(VNF) – Cuu Long Pharmaceutical Joint Stock Company (HoSE: DCL) and Allegens Company (India) recently signed a cooperation agreement on technology transfer and supply of raw materials for the production of the drug Molnupiravir to treat Covid-19.

Cuu Long Pharmaceutical produce drugs to treat Covid-19.

According to the signed agreement, DCL will receive technology transfer of Molnupiravir drug production according to the standards of countries around the world from Allegens Company. Allegens Company is committed to providing high-quality raw materials in bulk to DCL for the production of Molnupiravir.

It is known that the two sides are working closely to complete the procedures with the authorities as soon as possible.

According to a DCL representative, proactively looking for partners to produce Covid-19 treatment drugs aim to meet the Government’s urgent demand for Covid-19 treatment drugs in the country at present, contributing to increasing supply, reducing costs and reduce dependence on imported drugs to treat Covid-19 in the context of the current complicated epidemic situation.

“Besides the strength of producing empty capsules and syringes, the company’s development strategy is also directed to the production and distribution of high quality drugs at reasonable prices to provide patients with numerous drug treatment options”, emphasized the DCL representative.

Regarding the business situation, in the first 6 months of 2021, DCL recorded revenue of VND 359.3 billion, profit after tax of VND 44.7 billion, up 8.3% and 66.2% respectively compared to the same period last year. In 2021, DCL sets a business plan with total revenue of VND 805 billion and pre-tax profit of VND 110 billion.